Daša Skripová
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors represent a new pathway in the treatment of type 2 diabetes mellitus
(DM). This group of drugs affects one of the etiopathomechanism of type 2 diabetes mellitus origin and development:
the elevated glucose reabsorption in the proximal tubule of the kidney. European Medicines Agency (EMA) has
recently registered dapagliflozin, canagliflozin and empagliflozin for clinical use. In June 2014, dapagliflozin as the first
representative of this class of drug came to be used in Slovakia. Since January this year, canagliflozin, and since May
empagliflozin are available in the clinical practice, too. Many clinical studies have shown high efficacy and good tolerability
of SGLT-2 inhibitors, used as a second choice after metformin monotherapy failure.